GlycanAge is a pioneering healthtech company at the forefront of glycomics, the study of glycans, complex sugar molecules that are crucial biomarkers of biological age and immune system health. The company offers a scientifically validated biological age test, enabling consumers and healthcare professionals to track how lifestyle, nutrition, and interventions impact long-term health and ageing. With over 20 years of academic research and proprietary IP behind it, GlycanAge is positioned as the first-mover in commercialising glycan-based analysis.

We backed GlycanAge because it’s a first-mover in glycomics, with defensible IP and over 20 years of research underpinning its biological age test. The company sits at the heart of the longevity and preventative health trend, offering personalised insights that are gaining strong consumer and clinical demand. The founding team combines deep scientific expertise with commercial focus, and the business has already shown growing traction and strategic partnerships. We believe GlycanAge is well-positioned to become a leader in the next wave of personalised health diagnostics.